Skip to main content
SpringerLink
Log in

Head and Neck Mucosal Melanoma: Where Are We Now?

  • REVIEW
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To highlight recent and relevant treatment considerations while managing mucosal melanoma.

Recent Findings

Evidence is building to support the use of targeted therapy and immunotherapy while managing mucosal melanoma.

Summary

Surgical resection with postoperative radiotherapy plays a major role in managing resectable disease. Recent studies evaluate the addition of targeted, and immunotherapies with an attempt to determine the most efficacious sequence of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Bibliography

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Gal TJ, Silver N, Huang B. Demographics and treatment trends in sinonasal mucosal melanoma. Laryngoscope. 2011;121:2026–33.

    Article  Google Scholar 

  2. Christopherson K, Malyapa RS, Werning JW, Morris CG, Kirwan J, Mendenhall WM. Radiation therapy for mucosal melanoma of the head and neck. Am J Clin Oncol. 2015;38(1):87–9. https://doi.org/10.1097/COC.0b013e31828d73bf.

    Article  PubMed  Google Scholar 

  3. Seetharamu N, Ott PA, Pavlick AC. Mucosal melanomas: a casebased review of the literature. Oncologist. 2010;15:772–81.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Papaspyrou G, Garbe C, Schadendorf D, et al. Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors. Melanoma Res. 2011;21:475–82.

    Article  CAS  PubMed  Google Scholar 

  5. Edge SB American Joint Committee on Cancer. Ajcc Cancer Staging Manual 8th Ed. 8th ed. New York: Springer; 2017.

  6. Harwood AR, Cummings BJ. Radiotherapy for mucosal melanomas. Int J Radiat Oncol Biol Phys. 1982;8:1121–6.

    Article  CAS  PubMed  Google Scholar 

  7. Jethanamest D, Vila PM, Sikora AG, et al. Predictors of survival in mucosal melanoma of the head and neck. Ann Surg Oncol. 2011;18:2748–56.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Shibuya H, Takeda M, Matsumoto S, et al. The efficacy of radiation therapy for a malignant melanoma in the mucosa of the upper jaw: an analytic study. Int J Radiat Oncol Biol Phys. 1993;25:35–9.

    Article  CAS  PubMed  Google Scholar 

  9. Zenda S, Kawashima M, Nishio T, et al. Proton beam therapy as a nonsurgical approach to mucosal melanoma of the head and neck: a pilot study. Int J Radiat Oncol Biol Phys. 2011;81:135–9.

    Article  PubMed  Google Scholar 

  10. Cui C, Lian B, Zhang X, Wu D, Li K, Si L, Yang Y, Tian H, Zhou L, Chi Z, Sheng X, Kong Y, Mao L, Wang X, Bai X, Yan X, Li S, Dai J, Tang B, Wei X, Gershenwald J, Balch C, Guo J. An evidence-based staging system for mucosal melanoma: a proposal. Ann Surg Oncol. 2022;29:5221–34.

    Article  PubMed  Google Scholar 

  11. Moreno MA, Roberts DB, Kupferman ME, DeMonte F, El-Naggar AK, Williams M, Rosenthal DS, Hanna EY. Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D Anderson Cancer Center Cancer. 2010;116(9):2215–23. https://doi.org/10.1002/cncr.24976.

    Article  Google Scholar 

  12. Bachar G, Loh KS, O’Sullivan B, et al. Mucosal melanomas of the head and neck: the Princess Margaret Hospital experience. Head Neck. 2008;30:1325–31.

    Article  PubMed  Google Scholar 

  13. Penel N, Mallet Y, Mirabel X, Van JT, Lefebvre JL. Primary mucosal melanoma of head and neck: prognostic value of clear margins. Laryngoscope. 2006;116:993–5.

    Article  PubMed  Google Scholar 

  14. Lee SP, Shimizu KT, Tran LM, Juillard G, Calcaterra TC. Mucosal melanoma of the head and neck: the impact of local control on survival. Laryngoscope. 1994;104:121–6.

    Article  CAS  PubMed  Google Scholar 

  15. Almutuawa DM, Strohl MP, Gruss C, van Zante A, Yom SS, McDermott MW, El-Sayed IH. Outcomes of sinonasal mucosal melanomas with endoscopic and open resection: a retrospective cohort study. J Neurooncol. 2020;150(3):387–92. https://doi.org/10.1007/s11060-020-03449-0.

    Article  PubMed  Google Scholar 

  16. Lund VJ, Chisholm EJ, Howard DJ, et al. Sinonasal malignant melanoma: an analysis of 115 cases assessing outcomes of surgery, postoperative radiotherapy and endoscopic resection. Rhinology. 2012;50(2):203–10.

    Article  CAS  PubMed  Google Scholar 

  17. Swegal W, Koyfman S, Scharpf J, et al. Endoscopic and open surgical approaches to locally advanced sinonasal melanoma: comparing the therapeutic benefits. JAMA Otolaryngol Head Neck Surg. 2014;140(9):840–5.

    Article  PubMed  Google Scholar 

  18. Ledderose GJ, Leunig A. Surgical management of recurrent sinonasal mucosal melanoma: endoscopic or transfacial resection. Eur Arch Otorhinolaryngol. 2015;272(2):351–6.

    Article  CAS  PubMed  Google Scholar 

  19. Benlyazid A, Thariat J, Temam S, et al. Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study. Arch Otolaryngol Head Neck Surg. 2010;136:1219–25.

    Article  PubMed  Google Scholar 

  20. De Virgilio A, Costantino A, Canzano F, Accorona R, Mercante G, Ferreli F, Malvezzi L, Colombo G, Pellini R, Spriano G. Regional disease control in sinonasal mucosal melanoma: Systematic review and meta-analysis. Head Neck. 2021;43(2):705–15. https://doi.org/10.1002/hed.26537.

    Article  PubMed  Google Scholar 

  21. Temam S, Mamelle G, Marandas P, Wibault P, Avril MF, Janot F, Julieron M, Schwaab G, Luboinski B. Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer. 2005;103(2):313–9. https://doi.org/10.1002/cncr.20775.

    Article  PubMed  Google Scholar 

  22. Pandrangi VC, Mace JC, Abiri A, Adappa ND, Beswick DM, Chang EH, Eide JG, Fung N, Hong M, Johnson BJ, Kohanski MA, Kshirsagar RS, Kuan EC, Le CH, Lee JT, Nabavizadeh SA, Obermeyer IP, Palmer JN, Pinheiro-Neto CD, Smith TL, Snyderman CH, Suh JD, Wang EW, Wang MB, Choby G, Geltzeiler M. Recurrence patterns among patients with sinonasal mucosal melanoma: a multi-institutional study. Int Forum Allergy Rhinol. 2023. https://doi.org/10.1002/alr.23204.

    Article  PubMed  Google Scholar 

  23. Ma X, Wu Y, Zhang T, Song H, Jv H, Guo W, Ren G. The clinical significance of c-Kit mutations in metastatic oral mucosal melanoma in China. Oncotarget. 2017;8(47):82661–73. https://doi.org/10.18632/oncotarget.19746.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Satzger I, Schaefer T, Kuettler U, Broecker V, Voelker B, Ostertag H, Kapp A, Gutzmer R. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer. 2008;99(12):2065–9. https://doi.org/10.1038/sj.bjc.6604791.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327–34. https://doi.org/10.1001/jama.2011.746.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Kim KB, Alrwas A. Treatment of KIT-mutated metastatic mucosal melanoma. Chin Clin Oncol. 2014;3(3):35. https://doi.org/10.3978/j.issn.2304-3865.2014.08.02.

    Article  PubMed  Google Scholar 

  27. Flynn JP, Gerriets V. Imatinib. [Updated 2022 Jul 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551676/

  28. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O’Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013;31(26):3182–90. https://doi.org/10.1200/JCO.2012.47.7836.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kim KB, Eton O, Davis DW, Frazier ML, McConkey DJ, Diwan AH, Papadopoulos NE, Bedikian AY, Camacho LH, Ross MI, Cormier JN, Gershenwald JE, Lee JE, Mansfield PF, Billings LA, Ng CS, Charnsangavej C, Bar-Eli M, Johnson MM, Murgo AJ, Prieto VG. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008;99(5):734–40. https://doi.org/10.1038/sj.bjc.6604482.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Santeufemia DA, Palmieri G, Miolo G, Colombino M, Doro MG, Frogheri L, Paliogiannis P, Capobianco G, Madonia M, Cossu A, Lo Re G, Corona G. Current trends in mucosal melanomas: an overview. Cancers (Basel). 2023;15(5):1356. https://doi.org/10.3390/cancers15051356.

    Article  CAS  PubMed  Google Scholar 

  31. Amit M, Tam S, Abdelmeguid AS, Roberts DB, Takahashi Y, Raza SM, Su SY, Kupferman ME, DeMonte F, Hanna EY. Mutation status among patients with sinonasal mucosal melanoma and its impact on survival. Br J Cancer. 2017;116(12):1564–71. https://doi.org/10.1038/bjc.2017.125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Pracht M, Mogha A, Lespagnol A, Fautrel A, Mouchet N, Le Gall F, Paumier V, Lefeuvre-Plesse C, Rioux-Leclerc N, Mosser J, Oger E, Adamski H, Galibert MD, Lesimple T. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. J Eur Acad Dermatol Venereol. 2015;29(8):1530–8. https://doi.org/10.1111/jdv.12910.

    Article  CAS  PubMed  Google Scholar 

  33. Hsieh R, Nico MM, Camillo CM, Oliveira KK, Sangueza M, Lourenço SV. Mutational status of NRAS and BRAF genes and protein expression analysis in a series of primary oral mucosal melanoma. Am J Dermatopathol. 2017;39(2):104–10. https://doi.org/10.1097/DAD.0000000000000605.

    Article  PubMed  Google Scholar 

  34. Zebary A, Jangard M, Omholt K, Ragnarsson-Olding B, Hansson J. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases. Br J Cancer. 2013;109(3):559–64. https://doi.org/10.1038/bjc.2013.373.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Scherzad A, Stöth M, Meyer TJ, Haug L, Gehrke T, Schilling B, Meierjohann S, Scheich M, Hagen R, Gesierich A, Hackenberg S. Multimodal treatment and immune checkpoint inhibition in sinonasal mucosal melanoma: real-world data of a retrospective, single-center study. Eur Arch Otorhinolaryngol. 2023. https://doi.org/10.1007/s00405-023-08015-8

  36. Bai X, Mao LL, Chi ZH, Sheng XN, Cui CL, Kong Y, Dai J, Wang X, Li SM, Tang BX, Lian B, Zhou L, Yan XQ, Guo J, Si L. BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma. Neoplasma. 2017;64(4):626–32. https://doi.org/10.4149/neo_2017_419.

    Article  CAS  PubMed  Google Scholar 

  37. Long GV, Menzies AM, Scolyer RA. Neoadjuvant checkpoint immunotherapy and melanoma: the time is now. J Clin Oncol. 2023;41(17):3236–48. https://doi.org/10.1200/JCO.22.02575.

    Article  CAS  PubMed  Google Scholar 

  38. Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Kaufman HL, Seebach F, Lowy I, Yoo SY, Mathias M, Fenech K, Han H, Fury MG, Rischin D. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022;387(17):1557–68. https://doi.org/10.1056/NEJMoa2209813.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016;122(21):3354–62. https://doi.org/10.1002/cncr.30259.

    Article  CAS  PubMed  Google Scholar 

  40. Hamid O, Robert C, Ribas A, Hodi FS, Walpole E, Daud A, Arance AS, Brown E, Hoeller C, Mortier L, Schachter J, Long J, Ebbinghaus S, Ibrahim N, Butler M. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer. 2018;119(6):670–4. https://doi.org/10.1038/s41416-018-0207-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Lawlor RT, Mattiolo P, Mafficini A, Hong SM, Piredda ML, Taormina SV, Malleo G, Marchegiani G, Pea A, Salvia R, Kryklyva V, Shin JI, Brosens LA, Milella M, Scarpa A, Luchini C. Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions. Cancers (Basel). 2021;13(13):3119. https://doi.org/10.3390/cancers13133119.

    Article  CAS  PubMed  Google Scholar 

  42. Fusco MJ, West HJ, Walko CM. Tumor mutation burden and cancer treatment. JAMA Oncol. 2021;7(2):316. https://doi.org/10.1001/jamaoncol.2020.6371.

    Article  PubMed  Google Scholar 

  43. Burcher KM, Lantz JW, Gavrila E, Abreu A, Burcher JT, Faucheux AT, Xie A, Jackson C, Song AH, Hughes RT, Lycan T Jr, Bunch PM, Furdui CM, Topaloglu U, D’Agostino RB Jr, Zhang W, Porosnicu M. Relationship between tumor mutational burden, PD-L1, patient characteristics, and response to immune checkpoint inhibitors in head and neck squamous cell carcinoma. Cancers (Basel). 2021;13(22):5733. https://doi.org/10.3390/cancers13225733.

    Article  CAS  PubMed  Google Scholar 

  44. Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175–80. https://doi.org/10.1038/nature22071.

    Article  CAS  PubMed  Google Scholar 

  45. • Ho J, Mattei J, Tetzlaff M, Williams MD, Davies MA, Diab A, Oliva ICG, McQuade J, Patel SP, Tawbi H, Wong MK, Fisher SB, Hanna E, Keung EZ, Ross M, Weiser R, Su SY, Frumovitz M, Meyer LA, Jazaeri A, Pettaway CA, Guadagnolo BA, Bishop AJ, Mitra D, Farooqi A, Bassett R, Faria S, Nagarajan P, Amaria RN. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. Front Oncol. 2022;12:1001150. https://doi.org/10.3389/fonc.2022.1001150. (This study introduces a role for continued evaluation of neoadjuvant strategies for managing mucosal melanoma in a surgically resectable population.)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. D’Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, Savage KJ, Miller WH Jr, Mohr P, Marquez-Rodas I, Charles J, Kaatz M, Sznol M, Weber JS, Shoushtari AN, Ruisi M, Jiang J, Wolchok JD. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017;35(2):226–35. https://doi.org/10.1200/JCO.2016.67.9258.

    Article  PubMed  Google Scholar 

  47. Falcone R, Verkhovskaia S, Di Pietro FR, Poti G, Samela T, Carbone ML, Morelli MF, Zappalà AR, di Rocco ZC, Morese R, Piesco G, Marchetti P, Failla CM, De Galitiis F. Primary mucosal melanoma: clinical experience from a single Italian center. Curr Oncol. 2024;31(1):588–97.

    Article  PubMed  PubMed Central  Google Scholar 

  48. • Smart AC, Giobbie-Hurder A, Desai V, Xing JL, Lukens JN, Taunk NK, Sullivan RJ, Mooradian MJ, Hsu CC, Buchbinder EI, Schoenfeld JD. Multicenter evaluation of radiation and immune checkpoint inhibitor therapy in mucosal melanoma and review of recent literature. Adv Radiat Oncol. 2023;9(1):101310. https://doi.org/10.1016/j.adro.2023.101310. (A retrospective review of treatment outcomes of patients with localized and locally advanced mucosal melanoma who received a combination of radiation therapy and immune checkpoint inhibitor therapy with or without surgery. A heterogenous cohort limits the analysis, although 31% of patients demonstrated an objective response to initial multimodality immunotherapy treatment, vs 19% when managing recurrent disease.)

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Chang Gung University and Medical College, Taiwan, Republic of China

    Curtis Hanba

  2. Department of Otolaryngology-Head and Neck Surgery, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA

    Curtis Hanba & Ehab Hanna

  3. The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Ehab Hanna

Authors
  1. Curtis Hanba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ehab Hanna
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

C.H. and E.H. drafted and finalized the main manuscript text. All authors reviewed the manuscript.

Corresponding author

Correspondence to Ehab Hanna.

Ethics declarations

Competing Interests

The authors declare no competing interests.

Ethics Approval

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hanba, C., Hanna, E. Head and Neck Mucosal Melanoma: Where Are We Now?. Curr Oncol Rep 26, 421–425 (2024). https://doi.org/10.1007/s11912-024-01513-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-024-01513-w

Keywords

Search

Navigation